Investor profile
F-Prime Capital
CVC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
F-Prime Capital enables companies to turn their boldest ambitions into world-changing breakthroughs in life sciences, technology, healthtech + services, and crypto. With over 50 years of history and $5.3 billion under management, the firm operates without outside investors, allowing it to focus entirely on supporting entrepreneurs. In healthcare, F-Prime invests stage-agnostically across therapeutics, medtech, and healthtech + services; in technology, it focuses on enterprise software, fintech, frontier tech, and crypto. The firm's seasoned team of scientists, engineers, physicians, operators, and investors brings real-world expertise to help companies accelerate their path to scalable growth, and has co-founded over 35 portfolio companies from scratch across the Americas, Europe, and Asia.
Notable quotes
“2023 was a year of recovery in the fintech landscape. The public fintech correction has largely played out and most sectors are showing signs of recovery. While regulatory pressures and market corrections posed challenges, they also prompted fintech companies to innovate and prioritize sustainable growth.”
“F-Prime Capital is a leading global venture capital firm investing in healthcare and technology. We're proud to champion companies dedicated to directly shaping the future of medicine and technology. With more than $4.5 billion dollars under management and a global portfolio of over 300 companies, we are constantly searching for the next big thing to invest in; sometimes we'll start it ourselves – over 30 times and counting.”
“Our funds have become larger and reflect a growing international presence over the course of our history, but we stay true to our entrepreneurial roots thanks to our small, local teams. Connecting minds and driving innovation is a borderless effort.”
Team
Stephen Knight
President & Senior Managing Partner
Ketan Patel
Managing Partner
Betsy Mulé
Partner
Abdul Abdirahman
Partner
Raj Basak
Senior Associate
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Xaira Therapeutics | Series A | $1.0b | 2024-04 |
| Metsera | Series A | $290m | 2024-04 |
| Beam Therapeutics | Series A | — | 2018 |
| Toast | Series A | — | 2016 |
| Denali Therapeutics | Seed | — | 2015 |
| Benchling | Series A | — | 2018 |
| Flywire | Seed | — | 2013 |
| Devoted Health | Series A | — | 2017 |
| Innovent Biologics | Series A | — | 2011 |
| Blueprint Medicines | Series A | — | 2014 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| ARCH Venture Partners | 8 |
| Atlas Venture | 7 |
| Third Rock Ventures | 6 |
| OrbiMed | 5 |
| 5AM Ventures | 4 |
| Polaris Partners | 4 |
Fit check
Is F-Prime Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit